Radiopharmaceuticals for Prostate Cancer
Description: Medical oncologist Michael Morris of Memorial Sloan-Kettering's Genitourinary Oncology Service describes new injectable radiopharmaceutical agents used to treat bone metastases from castration-resistant prostate cancer. These alpha-emitting agents deliver high, lethal doses of radioactive energy over a small distance ). Because the energy they emit penetrates only through the depth of a small number of cells the process leads to fewer side effects than the (primarily palliative) older beta-emitting radiopharmaceutical agents. Memorial Sloan-Kettering was the first center to bring one of these alpha emitters, radium-223, to the United States. It was also the first institution to combine the use of the radiopharmaceutical with chemotherapy. The FDA approved the agent for commercial use in May 2013.
Shared By : mskcc
Posted on : 07/08/13
Added : 5 years ago